Pregled bibliografske jedinice broj: 979500
Cognitive, behavioral and metabolic effects of oral galactose treatment in the transgenic Tg2576 mice
Cognitive, behavioral and metabolic effects of oral galactose treatment in the transgenic Tg2576 mice // Neuropharmacology, 148 (2018), 50-67 doi:10.1016/j.neuropharm.2018.12.018 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 979500 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Cognitive, behavioral and metabolic effects of oral galactose treatment in the transgenic Tg2576 mice
Autori
Babić Perhoč, Ana ; Osmanović Barilar, Jelena ; Knezović, Ana ; Farkaš, Vladimir ; Bagarić, Robert ; Švarc, Alfred ; Grünblatt, Edna ; Riederer, Peter ; Šalković-Petrišić, Melita
Izvornik
Neuropharmacology (0028-3908) 148
(2018);
50-67
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
Alzheimer disease ; Galactose ; Metabolism ; Transgenic mice ; Positron-emission tomography ; Cognition
Sažetak
Alzheimer's disease (AD) is the most common neurodegenerative disorder associated with insulin resistance and glucose hypometabolism in the brain. Oral administration of galactose, a nutrient that provides an alternative source of energy, prevents and ameliorates early cognitive impairment in a streptozotocin- induced model (STZ-icv) of the sporadic AD (sAD). Here we explored the influence of 2- month oral galactose treatment (200 mg/kg/day) in the familial AD (fAD) by using 5- (5M) and 10- (10M) month-old transgenic Tg2576 mice mimicking the presymptomatic and the mild stage of fAD, and compared it to that observed in 7- month old STZ-icv rats mimicking mild-to- moderate sAD. Cognitive and behavioral performance was tested by Morris Water Maze, Open Field and Elevated Plus Maze tests, and metabolic status by intraperitoneal glucose tolerance test and fluorodeoxyglucose Positron- Emission Tomography scan. The level of insulin, glucagon-like peptide-1 (GLP-1) and soluble amyloid β1-42 (sAβ1-42) was measured by ELISA and the protein expression of insulin receptor (IR), glycogen synthase kinase-3β (GSK-3β), and pre-/post-synaptic markers by Western blot analysis. Although galactose normalized alterations in cerebral glucose metabolism in all Tg2576 mice (5M+2M ; 10M+2M) and STZ-icv rats, it did not improve cognitive impairment in either model. Improvement of reduced grooming behavior and normalization in reduced plasma insulin levels were seen only in 5M+2M Tg2576 mice while in 10M+2M Tg2576 mice oral galactose induced metabolic exacerbation at the level of plasma insulin, GLP-1 homeostasis and glucose intolerance, and additionally increased hippocampal sAβ1-42 level, decreased IR expression and increased GSK-3β activity. The results indicate that therapeutic potential of oral galactose seems to depend on the stage and the type/model of AD and to differ in the absence and the presence of AD-like pathology.
Izvorni jezik
Engleski
POVEZANOST RADA
Projekti:
HRZZ-IP-2014-09-4639 - TERAPIJSKI POTENCIJAL ORALNE GALAKTOZE U EKSPERIMENTALNOJ ALZHEIMEROVOJ BOLESTI (GALAD) (Melita Šalković, Petrišić) ( CroRIS)
Ustanove:
Institut "Ruđer Bošković", Zagreb,
Medicinski fakultet, Zagreb
Profili:
Alfred Švarc
(autor)
Melita Šalković-Petrišić
(autor)
Ana Babić Perhoč
(autor)
Ana Knezović
(autor)
Robert Bagarić
(autor)
Vladimir Farkaš
(autor)
Jelena Osmanović
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE